Much ADaM about nothing

ISSN： 1757-093X

Source： Pharmaceutical Programming, Vol.4, Iss.1-2, 2011-12, pp. : 45-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Case of Biotech-Derived Product Equivalence: Much Ado About Nothing?

Current Clinical Pharmacology, Vol. 1, Iss. 2, 2006-05 ,pp. : 147-156

Bentham Science Publishers

Access to resources Recommend Favorite

T2DM treatment targets scrutinised at ADA: nothing needs to change

Inpharma, Vol. 1, Iss. 1643, 2008-01 ,pp. : 6-7

Adis International

Access to resources Recommend Favorite

The dataset generation for survival analysis with the ADaM Basic Data Structure for Time-to-Event Analyses (ADTTE) standard

By Li Chengxin

Pharmaceutical Programming, Vol. 5, Iss. 1-2, 2012-12 ,pp. : 1-4

Maney Publishing

Access to resources Recommend Favorite

Approaches to creating ADaM subject-level analysis datasets (ADSL) for integrated analyses

By Freimark Nate

Pharmaceutical Programming, Vol. 5, Iss. 1-2, 2012-12 ,pp. : 61-64

Maney Publishing

Access to resources Recommend Favorite

Adenosine in the mammalian heart: nothing to get excited about

By Pelleg A. Kutalek S.P.

Trends in Pharmacological Sciences, Vol. 18, Iss. 7, 1997-07 ,pp. : 236-238

Elsevier

Access to resources Recommend Favorite